If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX(1-800-545-5979)
Cyramza ® (ramucirumab) injection
10 mg/mL solutionThis information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
CYRAMZA® (ramucirumab): Approval for Treatment of HCC
Cyramza (ramucirumab), as a single agent, is indicated for the treatment of HCC who have an AFP ≥400 ng/mL and have been treated with sorafenib.
On May 10, 2019, the FDA approved ramucirumab as a single agent for the treatment of patients with HCC who have an AFP ≥400 ng/mL and have been treated with sorafenib therapy.1
Enclosed Prescribing Information
CYRAMZA® (ramucirumab) injection, for intravenous use, Lilly
1. Cyramza [package insert]. Indianapolis, IN: Eli Lilly and Company; 2019.
Glossary
AFP = alpha-fetoprotein
FDA = Food and Drug Administration
HCC = hepatocellular carcinoma
Date of Last Review: March 28, 2019
Contact Lilly
Call Us
If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.
Available Mon - Fri, 9am - 7pm EST